I'm LongbridgeAI, I can summarize articles.Hemab Therapeutics reported a widened Q2 FY26 net loss of $24.15 million, driven by increased R&D and G&A expenses. Cash reserves surged to $457.5 million following IPO proceeds. The FDA endorsed moving sutacimig into Phase 3 trials, with initiation planned for late 2026. Additionally, the company unveiled HMB-003 for heavy menstrual bleeding, targeting first-in-human studies in late 2026.
- Hemab Therapeutics posted a Q2 net loss of $24.2 million, or $0.80 per share, versus a $12.2 million loss a year earlier. * R&D expense rose to $20.3 million from $12.9 million year over year; G&A climbed to $5.7 million from $3.2 million. * Cash, cash equivalents, and marketable securities jumped to $457.5 million from $163.5 million at March 31, boosted by $317.2 million IPO proceeds. * FDA endorsed sutacimig’s GT data package to move into a Phase 3 pivotal trial at 0.2 mg/kg weekly, with initiation planned in 2H 2026. * HMB-003 was unveiled for heavy menstrual bleeding, with first-in-human studies planned for 2H 2026 and initial clinical data targeted for mid-2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807446) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)